Prescribing direct-acting oral anticoagulants - Mind the evidence gap.
Affiliation
Barts Health NHS Trust; Queen Mary University of London; Sandwell and West Birmingham NHS Trust; University of BirminghamPublication date
2022-07-13
Metadata
Show full item recordAbstract
Direct-acting oral anticoagulants (DOACs) are licensed for the prevention of thromboembolism in non-valvular atrial fibrillation, amongst other indications. Prescribers use information derived from the summary of product characteristics which is based on the key trials supporting the DOAC's market authorisation. However, prescribers may not be aware of the limitations within these trials regarding underrepresentation of patient populations commonly encountered in clinical practice and how this may adversely impact them. This review highlights the gaps in the licensing evidence using four clinical vignettes that explore prescribing challenges in older adults, female patients, patients with obesity and patients from non-Europid ethnic backgrounds.Citation
Adeyeye E, Maniero C, Magavern EF, Ferner RE, McGettigan P. Prescribing direct-acting oral anticoagulants - Mind the evidence gap. Br J Clin Pharmacol. 2022 Nov;88(11):4724-4731. doi: 10.1111/bcp.15450Type
ArticlePMID
35771028Publisher
Wileyae974a485f413a2113503eed53cd6c53
10.1111/bcp.15450